MedTrace Logo

A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis

NCT05849727 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 195

Last updated 2025-02-20

No results posted yet for this study

Summary

To evaluate the efficacy and safety of TQH3821 in treated patients with moderate-to-severe active rheumatoid arthritis.

Conditions

Interventions

DRUG

TQH3821 tablets 200 mg

TQH3821 is a Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor.

DRUG

TQH3821 tablets matching placebo

TQH3821 tablets matching placebo without active substance.

Sponsors & Collaborators

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-30
Primary Completion
2025-01-15
Completion
2025-01-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05849727 on ClinicalTrials.gov